CoChat

Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study

Florakis, Dimos, Hung, Victor, Kaltsas, Gregory, Coyte, Donna, Jenkins, Paul J., Chew, Shern L., Grossman, Ashley B., Besser, G. Michael, Monson, John P. · 2000 · Clinical Endocrinology
Cited by 69

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To study the effects of short (6 months) and longer‐term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH‐deficient, hypopituitary adults. DESIGN: On‐going open study of GH treatment up to 24 months. Measurements were performed at baseline and at 6, 12, 18 months and 2 years during therapy (data shown at 6 months and 2 years only). Using a dose titration regimen the median GH dose used to achieve and maintain IGF‐I levels above the median, but below the upper limit of the age‐related reference range (median IGF‐I 202.5 μg/l, range 76–397 μg/l), was 1.2 IU daily (range 0.4–3 IU) [0.8 IU/day, males; 1.6 IU/day, females]. PATIENTS: Ninety GH‐deficient hypopituitary adults (54 female, median age 48 years, range 19–79 years) entered the study and 24 (14 female, median age 45 years, range 32–79 years) have concluded the 2 year period of assessment. MEASUREMENTS: Body mass index (BMI), waist and hip circumference ratio (WHR), fasting lipids, glucose and glycated haemoglobin (HbA 1c) levels were measured at 6 month intervals during GH therapy. RESULTS: Using the dose titration regimen, compared to pretreatment values, total and low density lipoprotein (LDL)‐cholesterol levels were significantly lower at 6 months (mean ± SEM, 5.61 ± 0.1 vs. 5.25 ± 0.1, and 3.85 ± 0.19 vs. 3.43 ± 0.26, respectively, P < 0.05), and were maintained throughout the study. Male patients had significantly lower pretreatment total and LDL cholesterol levels than females (mean ± SEM, 5.33 ± 0.16 mmol/l vs. 5.7 ± 0.12 mmol/l and 3.8 ± 0.23 mmol/l vs. 3.92 ± 0.29 mmol/l, respectively, P < 0.05). A decrease in total cholesterol was confined to patients with pretreatment total cholesterol levels above 5.8 mmol/l; patients with the highest pretreatment cholesterol levels (> 6.4 mmol/l) obtained the greatest cholesterol reduction (mean ± SEM, 7.13 ± 0.14 mmol/l vs. 5.76 ± 0.31 mmol/l, P < 0.05). A cholesterol‐lowering effect of GH therapy was evident in patients who had elevated pre‐GH total cholesterol levels even if they were already receiving and continuing lipid lowering medication (mean ± SEM, 5.62 ± 0.22 vs. 5.03 ± 0.285, P < 0.05). A modest increment in high density lipoprotein (HDL)‐cholesterol was evident at 18 months but there was no significant change in triglycerides at any time point. Fasting plasma glucose increased significantly at 6 months but remained within the reference range. Glycated haemoglobin increased significantly at 6 months and was maintained throughout the study; one patient developed frank diabetes mellitus while receiving treatment. There was a weak but significant correlation between the increment in glycated haemoglobin and pretreatment BMI (r = + 0.215, P < 0.05). CONCLUSION: The effect of GH on lowering total and low density lipoprotein‐cholesterol is more prominent in patients with higher pretreatment cholesterol levels and is evident even in patients receiving other lipid‐lowering medication. A modest increment in mean fasting glucose (within the reference range) and mean glycated haemoglobin persisted throughout the study. One patient developed diabetes mellitus. A GH replacement regimen using low dose and careful titration to avoid elevated IGF‐I levels and adverse effects is associated with sustained beneficial effects on circulating lipids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2000.01108.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 69

Metadata

Authors
Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P. J., Chew, S. L., Grossman, A. B., Besser, G. M., & Monson, J. P.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2000-10
Volume
53
Issue
4
Pages
453-459
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1970734380
Cited by
69
References
7
FWCI
4.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. https://app.cochat.ai/papers/10.1046/j.1365-2265.2000.01108.x
The paper
Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P. J., Chew, S. L., Grossman, A. B., Besser, G. M., & Monson, J. P. (2000). Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2000.01108.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.